Experimental antibodies aim to block cat allergy eye itch

NCT ID NCT07675811

Recruiting now Symptom relief Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see if the treatment reduces eye itching and redness after exposure to cat allergen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: freneslerbart and mevonlerbart (alone or combined as REGN-2Cat)
What this could lead to: If successful, this could offer a new way to prevent or reduce eye allergy symptoms in people allergic to cats, without needing daily medication.
What could go wrong: This is still experimental. The treatment may not work better than placebo, and side effects are possible. It is not a cure for cat allergy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC CONJUNCTIVITIS

Contacts and locations

Locations

Andover Eye Associates
RECRUITING

Andover, Massachusetts, 01810, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.